Science Explorer Back to mapMap
Discussion
Company · Radnor · United States

Zynerba Pharmaceuticals (United States)

zynerba.comROR OpenAlex
Research works
9
▼ 64% vs 2018-21
Citations
192
20.7 per fractional work
Top-10% rate
27.7%
all institutions 10.0%
Open access
43%
world 40%
International
31%
world 18%
Zynerba Pharmaceuticals (United States)

Not ranked overall: Zynerba Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Zynerba Pharmaceuticals (United States) work in?

In all years, 52% of research at Zynerba Pharmaceuticals (United States) is in Health Sciences, 43% in Life Sciences. Its largest fields are Medicine (49%), Biochemistry, Genetics and Molecular Biology (23%), Neuroscience (19%). It does 1.6× the world's share of Life Sciences.

Health Sciences: 5 fractional works · 51.7% of its workMedicine: 5 fractional works · 48.7% of its workPharmacology: 2 fractional works · 19.7% of its workPsychiatry and Mental health: 2 fractional works · 19.4% of its workSurgery: 0 fractional works · 4.3% of its workRheumatology: 0 fractional works · 2.2% of its workUrology: 0 fractional works · 1.2% of its workPhysiology: 0 fractional works · 0.9% of its workComplementary and alternative medicine: 0 fractional works · 0.6% of its workEpidemiology: 0 fractional works · 0.4% of its workHealth Professions: 0 fractional works · 1.8% of its workSpeech and Hearing: 0 fractional works · 1.8% of its workVeterinary: 0 fractional works · 1.2% of its workSmall Animals: 0 fractional works · 1.2% of its workLife Sciences: 4 fractional works · 43.1% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 23.1% of its workGenetics: 2 fractional works · 21.1% of its workPhysiology: 0 fractional works · 1.2% of its workClinical Biochemistry: 0 fractional works · 0.8% of its workNeuroscience: 2 fractional works · 19.2% of its workCognitive Neuroscience: 2 fractional works · 16.6% of its workEndocrine and Autonomic Systems: 0 fractional works · 1.2% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.9% of its workNeurology: 0 fractional works · 0.5% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.9% of its workToxicology: 0 fractional works · 0.9% of its workSocial Sciences: 0 fractional works · 5.2% of its workSocial Sciences: 0 fractional works · 2.7% of its workEducation: 0 fractional works · 2.7% of its workPsychology: 0 fractional works · 2.5% of its workClinical Psychology: 0 fractional works · 1.9% of its workExperimental and Cognitive Psychology: 0 fractional works · 0.6% of its workALL ITS WORKZynerbaPharmaceuticals…9fractional works, all years
Life Sciences43%Health Sciences52%Social Sciences5%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 8 fields, with their numbers
    1. Medicine548.7%
    2. Health Professions01.8%
    3. Veterinary01.2%
    1. Biochemistry, Genetics and Molecular Biology223.1%
    2. Neuroscience219.2%
    3. Pharmacology, Toxicology and Pharmaceutics00.9%
    1. Social Sciences02.7%
    2. Psychology02.5%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Zynerba Pharmaceuticals (United States)?

Ranked on the quality score, Terri B. Sebree and Nancy Tich lead among researchers whose main affiliation is Zynerba Pharmaceuticals (United States).

  1. 1 Terri B. Sebree United States · #1,483,061 worldwide 1.8k citations · 49 works
  2. 2 Nancy Tich United States · #2,797,720 worldwide 279 citations · 20 works
All ranked researchers at Zynerba Pharmaceuticals (United States)

What are the most cited papers from Zynerba Pharmaceuticals (United States)?

The most cited paper from Zynerba Pharmaceuticals (United States) is "Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients" (Nancy A. Haug, Claudia B. Padula, James E. Sottile et al., 2017), with 168 citations. Next come "Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle" (157) and "Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid" (114).

Most cited papers
#PaperReleasedCitations
1 Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients Nancy A. Haug, Claudia B. Padula, James E. Sottile et al. · Addictive Behaviors Open access 9 Mar 2017 168
2 Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle Gustavo González‐Cuevas, Rémi Martin‐Fardon, Tony M. Kerr et al. · Neuropsychopharmacology Open access 22 Mar 2018 157
3 Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid John J. Merrick, Brian Lane, Terri B. Sebree et al. · Cannabis and Cannabinoid Research Open access 8 Apr 2016 114
4 A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome Helen Heussler, Jonathan Cohen, Natalie Silove et al. · Journal of Neurodevelopmental Disorders Open access 2 Aug 2019 106
5 A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX) Elizabeth Berry‐Kravis, Randi Jenssen Hagerman, Dejan B. Budimirovic et al. · Journal of Neurodevelopmental Disorders Open access 25 Nov 2022 67
All 24 most cited papers, with filters and sorting

Which research topics does Zynerba Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Genetics and Neurodevelopmental Disorders, Attention Deficit Hyperactivity Disorder, Pancreatic function and diabetes and Cannabis and Cannabinoid Research.

Genetics and Neurodevelo…1Genetics and Neurodevelopmental Disorders: 1 fractional worksAttention Deficit Hyperactivity Disorder: 0 fractional worksPancreatic function and diabetes: 0 fractional worksCannabis and Cannabinoid Research: 0 fractional worksAutism Spectrum Disorder Research: 0 fractional works
GeneticsPsychiatry and Mental healthSurgeryPharmacology1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Genetics and Neurodevelopmental Disorders Genetics 1 works
  2. 2 Attention Deficit Hyperactivity Disorder Psychiatry and Mental health 0 works
  3. 3 Pancreatic function and diabetes Surgery 0 works
  4. 4 Cannabis and Cannabinoid Research Pharmacology 0 works
  5. 5 Autism Spectrum Disorder Research Cognitive Neuroscience 0 works
  6. 6 Epilepsy research and treatment Psychiatry and Mental health 0 works
  7. 7 Vagus Nerve Stimulation Research Neurology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available42.6%not open57.4%

World: 40% of research is openly available.

with international co-authors30.8%domestic only69.2%

World: 18% is written across borders.

How has Zynerba Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 64% lower than in 2018-2021.

2005201020152020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Radnor

All research institutions in Radnor

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Zynerba Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.